EISAI TO PRESENT DATA ON LECANEMAB and OTHER ALZHEIMER'S DISEASE RESEARCH AT THE AD/PD™ 2024 ANNUAL MEETING [Yahoo! Finance]
SYSMEX CORP UNSP/ASDR (SSMXY)
NASDAQ:AMEX Investor Relations:
sysmex.co.jp/en/ir/index.html
Company Research
Source: Yahoo! Finance
latest findings on lecanemab (U.S. brand name: LEQEMBI ® ), Eisai's anti-amyloid beta (Aß) protofibril* antibody for the treatment of Alzheimer's disease (AD), at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD™) from March 5-9 in Lisbon, Portugal , and virtually. The lecanemab data and additional research findings from Eisai's AD portfolio will be featured in 18 presentations, including ten oral presentations. Eisai will present five oral presentations and one poster presentation on lecanemab results. From the Phase 3 Clarity AD study in subjects with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD dementia (collectively known as early AD) with confirmed brain Aß accumulation, presentations will include data on the effect of lecanemab treatment on tau accumulation in whole brain regions, and outcomes of long-term efficacy of lecanemab. In addition, the differences in the binding properti
Show less
Read more
Impact Snapshot
Event Time:
SSMXY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SSMXY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SSMXY alerts
High impacting SYSMEX CORP UNSP/ASDR news events
Weekly update
A roundup of the hottest topics
SSMXY
News
- Sysmex America Begins Selling Hemostasis Instruments and Reagents Under the Sysmex Brand in the United StatesPR Newswire
- Asia-Pacific Next-Generation IVD Market Report 2023-2033: Molecular Diagnostics, Genomics, and Next-Generation Sequencing (NGS) are Anticipated to Play Pivotal Roles in Future Growth [Yahoo! Finance]Yahoo! Finance
- Asia-Pacific's Next-Generation IVD Market Worth $42+ Billion by 2033: Key Insights by Type, End-user and Country [Yahoo! Finance]Yahoo! Finance
- Asia-Pacific Measurable/Minimal Residual Disease (MRD) Testing Market Analysis 2023-2033 - Medicare Expansion and Rising Consumer Awareness Driving Growth [Yahoo! Finance]Yahoo! Finance
- Asia-Pacific MRD Testing Research Report 2024: Market to Grow by Over $1 Billion to 2033, Driven by Precision Medicine Revolution in Early Detection [Yahoo! Finance]Yahoo! Finance